Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
1581 results about "Estrogen" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Estrogen, or oestrogen, is the primary female sex hormone. It is responsible for the development and regulation of the female reproductive system and secondary sex characteristics. There are three major endogenous estrogens in females that have estrogenic hormonal activity: estrone, estradiol, and estriol. The estrane steroid estradiol is the most potent and prevalent of these.
Method of increasing testosterone and related steroid concentrations in women
InactiveUS20030022877A1Organic active ingredientsPharmaceutical non-active ingredientsHormones regulationCvd risk
The present invention relates to methods, kits, combinations, and compositions for treating, preventing or reducing the risk of developing a testosterone deficient disorder, or the symptoms associated with, or related to a testosterone deficient disorder in a subject in need thereof. The present invention also relates to a method of administering a steroid in the testosterone synthetic pathway to a subject in need thereof. In addition, the methods, kits, combinations and compositions may be used in conjunction with other pharmaceutical agents effective at treating, preventing, or reducing the risk of developing a testosterone deficient disorder. The present invention also can also be used in conjunction with a pharmacologically effective amount of an estrogenic hormone. Furthermore, the methods, kits, combinations and compositions can be used in conjunction with a pharmacologically effective amount of another steroid or pharmaceutical agent that increases serum testosterone levels in a mammal.
Owner:UNIMED PHARMA LLC
Inhibitors of type 5 and type 3 17beta-hydroxysteroid dehydrogenase and methods for their use
Novel methods of medical treatment and / or inhibition of development of diseases are disclosed for diseases that are sensitive to androgenic or estrogenic activity. The treatments utilize inhibitors of type 5 and / or type 3 17beta-hydroxysteroid dehydrogenase. Novel inhibitors of type 5 17beta-hydroxysteroid dehydrogenase are also disclosed, as are novel inhibitors of type 3 17beta-hydroxysteroid dehydrogenase.
Owner:ENDORES & DEV
Method of increasing testosterone and related steroid concentrations in women
InactiveUS20050152956A1Organic active ingredientsPharmaceutical delivery mechanismHormones regulationCvd risk
The present invention relates to methods, kits, combinations, and compositions for treating, preventing or reducing the risk of developing a testosterone deficient disorder, or the symptoms associated with, or related to a testosterone deficient disorder in a subject in need thereof. The present invention also relates to a method of administering a steroid in the testosterone synthetic pathway to a subject in need thereof. In addition, the methods, kits, combinations and compositions may be used in conjunction with other pharmaceutical agents effective at treating, preventing, or reducing the risk of developing a testosterone deficient disorder. The present invention also can also be used in conjunction with a pharmacologically effective amount of an estrogenic hormone. Furthermore, the methods, kits, combinations and compositions can be used in conjunction with a pharmacologically effective amount of another steroid or pharmaceutical agent that increases serum testosterone levels in a mammal.
Owner:LABORATORIES BESINS INTERNATIONAL SAS
Tablet-in-tablet compositions
Owner:WYETH LLC
Methods for reducing the risk of breast cancer in and improving the health of women
InactiveUS6901278B1Reduce the possibilityReduce doseUltrasonic/sonic/infrasonic diagnosticsMicrobiological testing/measurementHormone replacementTreatment options
The subject invention provides methods for evaluating women in designing appropriate menopausal and postmenopausal therapies to match the particular needs of the individual. In one embodiment, the subject invention provides methods for evaluating particular factors in menopausal and postmenopausal women that are then taken into account in identifying a therapy program to promote good health and reduce the risk of any adverse health effects as a result of the therapy, specifically the role of hormone induced / associated breast cancer. More specifically, the subject invention includes methods for evaluating menopausal and postmenopausal women to determine whether hormone replacement therapy is appropriate in this regard, and if so, the specifics of how that therapy is to be administered. The subject invention, by incorporating various factors into a comprehensive, function breast hormone profile, allows for the identification of untreated women with estrogen-related metabolic abnormalities that may increase the risk of breast cancer. The subject invention determines specific therapies to correct and / or inhibit the aberrant biosynthetic pathways, and thus, the risk of cancer.
Owner:THE BRAIN HEALTH PROJECT LLC
Estrogen compositions for vaginal administration
ActiveUS20070004694A1Organic active ingredientsPharmaceutical delivery mechanismPharmaceutical SubstancesPharmacology
Pharmaceutical gel compositions containing estrogen for vaginal administration, as well as a method of making the same, are disclosed.
Owner:ALLERGAN THERAPEUTICS LLC
Dietary supplements comprising soy hypocotyls containing at least one isoflavone
InactiveUS6497906B1Restore balanceHigh incidenceBiocidePeptide/protein ingredientsFood additiveHypocotyl
Owner:NOVOGEN RES
Compounds and methods for the treatment of urogenital disorders
InactiveUS6987129B2Reduce painLess discomfortBiocidePeptide/protein ingredientsDiseaseFemale Sexual Arousal Disorder
The present invention provides methods for treating a variety of urogenital disorders, such as, for example, vaginismus, dyspareunia, vulvodynia (including vulvar vestibulitis), interstitial cystitis, nonspecific urethriris (i.e., nonspecific pain and / or burning of the urinary tract) and sexual dysfunctions, such as, for example, female sexual arousal disorders and female sexual orgasmic disorders, using a variety of compounds, including, but not limited to, NO donors, calcium channel blockers, cholinergic modulators, α-adrenergic receptor antagonists, β-adrenergic receptor agonists, phosphodiesterase inhibitors, cAMP-dependent protein kinase activators (e.g., cAMP mimetics), superoxide scavengers, potassium channel activators, estrogen-like compounds, testosterone-like compounds, benzodiazepines, adrenergic nerve inhibitors, antidiarrheal agents, HMG-CoA reductase inhibitors, smooth muscle relaxants, adenosine receptor modulators, adenylyl cyclase activators, endothelin receptor antagonists, bisphosphonates and cGMP-dependent protein kinase activators (e.g., cGMP mimetics).
Owner:STREHKEHN INT LTD
Natural combination hormone replacement formulations and therapies
ActiveUS20130129818A1Improve complianceOrganic active ingredientsBiocideHormone replacementEstradiol.free
Estrogen and progesterone replacement therapies are provided herein. Among others, the following formulations are provided herein: solubilized estradiol without progesterone; micronized progesterone without estradiol; micronized progesterone with partially solubilized progesterone; solubilized estradiol with micronized progesterone; solubilized estradiol with micronized progesterone in combination with partially solubilized progesterone; and solubilized estradiol with solubilized progesterone.
Owner:THERAPEUTICSMD
Benzopyran-containing compounds and method for their use
InactiveUS6060503AAvoid conversionEasy to synthesizeBiocideOrganic compound preparationDiseaseBenzopyran
Certain benzopyran antiestrogens are disclosed for treating estrogen sensitive diseases such as breast cancer. Prodrug forms provide ease of manufacturing, good shelf life, and bioavailability, and preferred stereoisomers are shown to be more effective than racemic mixtures.
Owner:ENDORES & DEV
Method of increasing testosterone and related steroid concentrations in women
InactiveUS20040092494A9Organic active ingredientsPharmaceutical non-active ingredientsHormones regulationCvd risk
The present invention relates to methods, kits, combinations, and compositions for treating, preventing or reducing the risk of developing a testosterone deficient disorder, or the symptoms associated with, or related to a testosterone deficient disorder in a subject in need thereof. The present invention also relates to a method of administering a steroid in the testosterone synthetic pathway to a subject in need thereof. In addition, the methods, kits, combinations and compositions may be used in conjunction with other pharmaceutical agents effective at treating, preventing, or reducing the risk of developing a testosterone deficient disorder. The present invention also can also be used in conjunction with a pharmacologically effective amount of an estrogenic hormone. Furthermore, the methods, kits, combinations and compositions can be used in conjunction with a pharmacologically effective amount of another steroid or pharmaceutical agent that increases serum testosterone levels in a mammal.
Owner:UNIMED PHARMA LLC
Treatment of conditions that present with low bone mass by continuous combination therapy with selective prostaglandin ep4 receptor agonists and an estrogen
InactiveUS20070191319A1High cure rateLong bone extension is enhancedBiocideSkeletal disorderPresent methodCarboxylic acid
This invention is directed to methods for treating conditions which present with low bone mass in a patient in need thereof using continuous combination therapy with a synergistically effective combination of an EP4 receptor selective agonist or a pharmaceutically acceptable salt thereof, such as 5-(3-{2S-[3R-hydroxy-4-(3-trifluoromethyl-phenyl)-butyl]-5-oxo-pyrrolidin-1-yl}-propyl)-thiophene-2-carboxylic acid or a pharmaceutically acceptable salt thereof; and an estrogen or a pharmaceutically effective salt thereof, The present methods are useful for treating conditions that present with low bone mass including osteoporosis, osteotomy, osteoporotic fracture, childhood idiopathic bone loss, periodontitis and low bone mass and for enhancing bone healing following facial reconstruction, maxillary reconstruction or mandibular reconstruction, inducing vertebral synostosis, enhancing long bone extension, enhancing the healing rate of a bone graft or a long bone fracture or enhancing prosthetic ingrowth in a patient in need thereof.
Owner:PFIZER INC
Use of Δ5-androstene-3β-ol-7,17-dione in the treatment of lupus erythematosus
Lupus erythematosus can be treated by administering therapeutic amounts of Δ5-androstene-3β-ol-7,17-dione and metabolizable precursors thereof, such as Δ5-androstene-3b-acetoxy-7,17-dione, which are readily metabolized in vivo to Δ5-androstene-3β-ol-7,17-dione but are not appreciably metabolizable in vivo to androgens, estrogens or dehydroepiandrosterone. Such treatment can be prophylactic, ameliorative or curative in nature.
Owner:INTERHEALTH NUTRACEUTICALS
Phytoestrogen supplements prepared from pomegranate material including pomegranate seeds
A phytoestrogen supplement and methods of preparation are described. The basis of the oral phytoestrogen supplement was a preparation of the pomegranate material, preferably pomegranate seeds, which were contacted with an appropriate solvent as described below, preferably including water and ethanol. Preferably, the supplement also included an herbal mixture, including schizandra berries and Chinese asparagus root, and most preferably including Chinese licorice root and Chinese angelica root. The phytoestrogen supplement can also be prepared from pomegranate material alone without the addition of other herbals, which involves fermenting the pomegranate material including the pomegranate seeds. The basis of topical phytoestrogen supplements was a mixture of a preparation of the pomegranate material, preferably pomegranate seeds, which were pressed as described below to produce pomegranate oil, and of the coconut milk. Preferably, the supplements also included schizandra berries and Chinese asparagus root.
Owner:RIMONEST
Agent for treating eye diseases
An agent for treating various kinds of diseases which contains at least one selected from the group consisting of sexual steroid hormone such as estrogen or its metabolites, its derivative, structural analogues thereof, estrogen acting substance or SERM non-feminizing estrogen (non-hormonal estrogen), and an activator of sirtuin and has a form of eye drops or eye washes, oral preparation, etc. An agent for treating eye diseases which has excellent treatment effects, reduced in side action can be provided.
Owner:ADVANCED MEDICINE RES INST
Estrogen compositions for vaginal administration
Pharmaceutical gel compositions containing estrogen for vaginal administration, as well as a method of making the same, are disclosed.
Owner:WARNER CHILCOTT CO LLC
Transdermal matrix system
PCT No. PCT / FR96 / 01494 Sec. 371 Date Mar. 26, 1998 Sec. 102(e) Date Mar. 26, 1998 PCT Filed Sep. 25, 1996 PCT Pub. No. WO97 / 11687 PCT Pub. Date Apr. 3, 1997A novel transdermal matrix system for the percutaneous delivery of a hormone, including a carrier and an adhesive matrix, is disclosed. The matrix includes (a) 39-61 parts by weight of an ethylene / vinyl acetate copolymer, (b) 12-17 parts by weight of 2-octyldodecyl myristate, (c) 5-17 parts by weight of diethyl phthalate, (d) 10-16 parts by weight of a compound selected from N-alkyl-2-pyrrolidones, wherein the alkyl group is a C4-15 group, and (e) 1-12 parts by weight of at least one hormone selected from the group consisting of oestrogenic and progestogenic components. A method for preparing said transdermal matrix system and the therapeutical use of said system are also disclosed.
Owner:LABES DHYGIENE & DE DIETETIQUE L H D
Use of isoflavones to prevent hair loss and preserve the integrity of existing hair
The present invention is an orally- or topically-administrable composition for preventing and treating hair loss. The invention is a plant or plant extract containing isoflavones having a weak estrogen activity. The invention further includes methods for using the invented composition to prevent and treat hair loss.
Owner:NATURE'S SUNSHINE PRODUCTS
Method and composition for restoration of age related tissue loss in the face or selected areas of the body
InactiveUS20060073178A1Restoring age related tissue lossEasy to produceCosmetic preparationsBiocideInsulin-like growth factorThyroid hormones
A treatment method for restoring of age related tissue loss in the face or selected areas of the body is disclosed which includes injecting an injectable composition containing a growth factor and hyaluronic acid as a carrier into the dermis, the hypodermis, or both, in various areas of the face, or selected areas of the body of a person to stimulate collagen, elastin, or fat cell production, thereby restoring age related tissue loss in the face and selected areas of the body. Further disclosed is an injectable composition for restoring of age related tissue loss in the face and selected areas of the body, which contains a growth factor and hyaluronic acid as a carrier for providing time release of the growth factor into tissues. The growth factor can be insulin, insulin-like growth factor, thyroid hormone, fibroblast growth factor, estrogen, retinoic acid, or their combinations.
Owner:CELLHEALTH TECH
9-alpha-substituted estratrienes as selectively active estrogens
Owner:BAYER INTELLECTUAL PROPERTY GMBH
Methods of making, using and pharmaceutical formulations comprising 7alpha, 11beta-dimethyl-17beta-hydroxyestra-4, 14-dien-3-one and 17 esters thereof
InactiveUS7196074B2High yieldPositively affectingBiocideOrganic active ingredientsParenteral Dosage FormKetone
Owner:US DEPT OF HEALTH & HUMAN SERVICES
17Beta-Hydroxysteroid Dehydrogenase Type 1 Inhibitors for the Treatment of Hormone-Related Diseases
The invention relates to the use of non-steroidal 17beta-hydroxysteroid dehydrogenase type 1 inhibitors for the treatment and prophylaxis of hormone-dependent, particularly estrogen-dependent, diseases. The invention further relates to suitable inhibitors and to a method for the production thereof.
Owner:UNIV DES SAARLANDES
Natural combination hormone replacement formulations and therapies
Owner:THERAPEUTICSMD INC
Estrogen receptor modulators and uses thereof
Owner:RUTGERS THE STATE UNIV
Compositions and methods for treating estrogen-dependent diseases and conditions
A pharmaceutical composition for the treatment of an estrogen-dependent disease or condition comprises: (1) at least one polysaccharide selected from the group consisting of an alginate and a fucoidan in a quantity effective to treat an estrogen-dependent disease or condition; and (2) a pharmaceutically acceptable carrier. The composition can include both an alginate and a fucoidan. The composition can include other ingredients such as at least one compound selected from the group consisting of diindolylmethane and indole-3-carbinol in a quantity sufficient to inhibit the activity of estrogen. Methods for use of the composition for the treatment of an estrogen-dependent disease or condition, especially endometriosis, are described.
Owner:CONCOURSE HEALTH SCI
Treatment of Meconium Aspiration Syndrome with Estrogens
ActiveUS20100184736A1Reduce incidenceReduce morbidityOrganic active ingredientsPharmaceutical delivery mechanismSuppositoryNon invasive
One aspect of the present invention relates to the use of an estrogen in the treatment of Meconium Aspiration Syndrome (MAS) in a newborn infant, said treatment comprising administering an effective amount of estrogen to said newborn infant within 7 days after birth. The present treatment offers the advantage that estrogens can be administered using non-invasive modes of administration, e.g. oral or rectal administration. Other aspects of the present invention relate to a suppository for use in newborn infants comprising at least 1 μg of estrogen and to an oral applicator comprising a container holding an aqueous liquid containing micronised estetrol and a metering dispenser for metering the liquid into the oral cavity of a newborn infant.
Owner:ESTETRA SRL
Estrieno[3,2-b]/[3,4-c]pyrrole derivatives useful as modulators of the estrogen receptors
![Estrieno[3,2-b]/[3,4-c]pyrrole derivatives useful as modulators of the estrogen receptors](https://images-eureka.patsnap.com/patent_img/f250b60a-44c8-42bc-80f9-9cb841814e02/US07074779-20060711-C00001.png "Estrieno[3,2-b]/[3,4-c]pyrrole derivatives useful as modulators of the estrogen receptors")
![Estrieno[3,2-b]/[3,4-c]pyrrole derivatives useful as modulators of the estrogen receptors](https://images-eureka.patsnap.com/patent_img/f250b60a-44c8-42bc-80f9-9cb841814e02/US07074779-20060711-C00002.png "Estrieno[3,2-b]/[3,4-c]pyrrole derivatives useful as modulators of the estrogen receptors")
![Estrieno[3,2-b]/[3,4-c]pyrrole derivatives useful as modulators of the estrogen receptors](https://images-eureka.patsnap.com/patent_img/f250b60a-44c8-42bc-80f9-9cb841814e02/US07074779-20060711-C00003.png "Estrieno[3,2-b]/[3,4-c]pyrrole derivatives useful as modulators of the estrogen receptors")
Owner:ORTHO MCNEIL PHARM INC
Mercaptophenyl naphthyl methane compounds and synthesis thereof
Novel mercaptophenyl naphthyl methane compounds, their pharmaceutically acceptable salts and compositions comprised thereof are useful for the prevention or treatment of various medical indications associated with estrogen dependent diseases or syndromes related to osteoporosis, bone loss, bone formation, cardiovascular disorders, neurodegenerative disorders, menopausal disorders, physiological disorders, diabetes disorders, prostatic carcinoma, cancer of breast, cancer of uterus, cancer of the cervix and cancer of the colon, threatened or habitual abortion, obesity, ovarian development or function, post-partum lactation and depression.
Owner:COUNCIL OF SCI & IND RES
Estrogen beta receptor agonists to prevent or reduce the severity of cardiovascular disease
A method for preventing or treating vascular hyperreactivity in which a chemical compound that is an estrogen beta receptor agonist is administered to a subject suffering from or at risk of vascular hyperreactivity. Preferably, the administration is topically to the skin.
Owner:DIMERA
Combination hormone replacement therapy (HRT) and melatonin to prevent and treat mammary cancer
ActiveUS20110028439A1Reduce mammary cancer incidenceTreat symptomsBiocideOrganic active ingredientsReceptorHormone replacement
A combination hormone and melatonin therapy is provided to reduce the risk of developing, or to reduce the severity of, breast cancer by administering at least one estrogen hormone and optionally at least one progesterone-receptor-binding compound or composition and melatonin together, preferably at normal bed time.
Owner:DUQUESNE UNIVERSITY
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com